5/12/18 your patient takes speaker disclosure medical ... · 5/12/18 3 california medical marijuana...
TRANSCRIPT
5/12/18
1
YourPatientTakesMedicalMarijuana?EvidenceBasedResearchinActionJennyRaybin,MSN,RN,CPNPAssociateProfessorofPediatrics
(MollyHemenway,DNP,DNP,CPNPSeniorInstructorofPediatrics)
UniversityofColoradoSchoolofMedicineChildren’sHospitalColorado
SpeakerDisclosure
• JennyRaybinhasnoindustryrelationshipstodisclose.
• JennyRaybinwilldiscussoff-labeluse.
Areyouhearingthiseverywhereyouturn?
http://people.com/movies/ricki-lake-marijuana-cancer-treatment/
Introduction• Over6,000childrenareregisteredusersofmarijuanain
Colorado(about8,000inCalifornia)• Manypediatriconcologypatientsreportmedicalmarijuana
(MMJ)use.• ClinicaltrialsinadultshaveexaminedMMJforcancer-related
symptoms.• Newresearch
• MMJinanticancertherapy• MMJreceptorsontumorcells• PotentialroleforMMJasanimmunomodulator
• FewpediatriconcologystudieshaveevaluatedMMJ.
Objectives
HistoryLegality:ColoradoandCalifornia—beststatesever!DefinitionsandProductInformationEvidenceinSelectedConditionswithCaseStudiesHowHospitalsRespondResearchNursingimplications
History
1970:ClassifiedasSchedule1substance1988:DEAjudgerecommendedMJbereclassifiedasscheduledII(overruled)1985:FDAapproveddronabinol(Marinol)
1996:CaliforniapassesacttolegalizeMMJ
5/12/18
2
WhereisMedicalMarijuanaLegal?
MedicalMarijuanaLegalizedRecreationalMarijuanaLegalizedNoLawsLegalizingMarijuana
AsofNovember11,2016.Source:http://www.governing.com/gov-data/state-marijuana-laws-map-medical-recreational.html
ColoradoSpecificLegality ColoradoSpecificLegality
MarijuanainColoradoRetailhasincreasedandMedicalhasdecreased
since2016
NumberofLicensedRetailMarijuanaBusinessesasof
May 1,2018
Stores 528Cultivations 741
ProductManufacturers 286
TestingFacilities 12
NumberofLicensedMedicalMarijuanaBusinessesasof
May1,2018
Centers 497Cultivations 734
ProductManufacturers 253
TestingFacilities 14
CaliforniaLegality
• SimilartoColorado• Seriousmedicalcondition(referstoADA):
acquiredimmunedeficiencysyndrome(AIDS);anorexia;arthritis;cachexia(wastingsyndrome);cancer;chronicpain;glaucoma;migraine;persistentmusclespasms(i.e.,spasmsassociatedwithmultiplesclerosis);seizures(i.e.,epilepticseizures);severenausea;anyotherchronicorpersistentmedicalcondition
• Proofofresidency• ID• MDrecommendation• Fees
5/12/18
3
CaliforniaMedicalMarijuanaCardNumbers
• Currenttotal:99,843• Peakyearwas2009-10with12,659• Trendingdownwithabout6,000/yr and2017-18
having5,435
https://www.cdph.ca.gov/Programs/CHSI/Pages/MMP-Card-Data.aspxUpdated4/3/18
Definitions
MMJ:medicinalmarijuanaCannabis:synonymouswithmarijuana
—C.sativa,C.indica,C.ruderalis
Cannabinoids:chemicalcompoundsthatinteractwithcannabinoidreceptorsinthebody.Therearemorethan100cannabinoidsderivedfromcannabis.
Endocannabinoids:endogenousagonistsofCB1&CB2receptors—Anandamide,2-Archidonoylglycerol(2-AG)
Definitions
∆9THC:tetrahydrocannabinol(agonistofCB1)
—Principalpsychoactivecannabinoid—hasthemostmedicalclaims
CBD:Cannabidiol(lowaffinityforCB1andCB2,5HT1Aagonist)
—Minimalpsychoactiveeffects—Hasthemostmedicalpromise—Inhibitsbreakdownofanandamide
CannabinoidReceptors
Products
Pharmaceuticalproducts
Smokedcannabisflower(joint,pipe,blunt)
Vaporizedgroundleaf
Vaporizedconcentratedoil(shatter/wax)
Dabbedconcentrate
Ediblebakedgoods,candies,chocolates
Oraltincturesandoils
Cannabisinfusedtopicalcreams,lotions,oils
Transdermalpatches
Cannabinoid-BasedMedications
• SyntheticTHCderivatives(FDAapproved)• dronabinol(Marinol®,Syndros®)- scheduleIII• nabilone(Cesamet®)- scheduleII• BindtoCB1receptorswithhighaffinityandefficacy,onset
ofaction30-90min
• Epidiolex®- (investigational/expandedaccessprogram),concentratedCBDoil(>98%CBD)
• Nabiximols(Sativex®)oromucosalspray(notavailableintheUS)—THC/CBD(1:1)combinationcannabisextract,onsetofaction30-150min
5/12/18
4
PKofproducts
Inhaled:Tmax:3-10min,Duration:1-4hours,t1/2:~19hours
Oral/Mucosal:Tmax:1-3hours,Duration:4-10hours
Transdermal:Tmax:1.4hours,Duration:48hours,t1/2:~7days
THCDose-RelatedEffects
Lowdose:<7mginconsistenteffects
IntermediateDose:7-18mgreliablepharmacologiceffectsIncreasedheartrateDecreasedbloodpressureLowerocularpressure;reddeningofeyes
IntensifiedvisualandauditoryperceptionDecreasedattention,Cognitiveperformance– impairedonsequentialtaskswithmultiplestepsMoodeffects– euphoria;laughter,anxietyDrymouthBloodGlucoseDrop- “munchies”Reducednauseaandvomiting(anti-emeticaction)
HighDose: >18mg->undesirablepharmacologiceffectsNausea/VomitingDelusions,HallucinationsParanoia,AnxietyConfusionDepersonalization
TheEvidence MMJforPain:Felix
• 16yearoldwiththalamicanaplasticPXA• Treatedwithsurgery,radiation,andchemotherapy• Headachepainwasthemostdifficulttocontrol• Receivednervepainmeds,opioids,Botoxinjection• Thalamicpainsyndrome• MMJwasthemosteffective• Difficultywithcross-discipline
management
Page: 84 of 160Page: 84 of 160 IM: 84 SE: 15IM: 84 SE: 15Compressed 7:1Compressed 7:1
ChronicPainIn2014- 94%onColoradoMedicalCardholdersreportedseverepainasamedicalcondition
Survey-baseddatainMichiganshowed64%reductioninopioidusewithcannabisinpainpatients5systematicreviewsalldemonstratethatcannabinoidshaveamodesteffectonpain
Whitingetal2015-
28randomizedtrialsinpatientswithpain(chronicneuropathymostcommon)
22evaluatedplant-derived(nabiximols,plants,oralmucosaspray,oralTHC)8trials(nabiximolandplant-derived)showedMMJincreasedoddsforpainimprovementby40%vscontrol(placeboinmosttrials)Notenoughpowertotestfordifferencesbetweenpainconditions
ConclusionforChronicPain
MajorityofthestudiesweredoneoutsideoftheU.S.onnabiximols
TheU.S.studiesweredoneonflowersvaporizedorsmokedprovidedbyNIDA
2015- over500,000unitsofediblessoldinColoradoalone,whichdoesnotincludetopicalformssold
ThereisevidencecannabisisbeneficialforchronicpaininADULTSbutthereisapaucityofdataofdosagesandroutes
5/12/18
5
WhyareyoumovingtoColorado?
• Annie,9yo withmultiplyrecurrent,metastaticretinoblastoma
• Initiallytreatedoutofstate• MovedtoColoradoforMMJ• Admittedforsymptoms• Whoistheprimaryteam?• Palliativecare• Supportsystem
Page: 59 of 156Page: 59 of 156 IM: 59 SE: 801IM: 59 SE: 801
CancerSystematicReview- Rochaet.al2014
35studiesontheantitumoreffectsofcannabinoidsingliomas.Only1studyinhumans,16invivosamplesAllofthestudiesinthisreview,exceptone,showedthatcannabinoidsarecapableofselectivelykillingtumorcellsIncontrasttoitspro-apoptoticandantitumoreffectinvarioustypesoftumors,cannabinoidsprotectnormalcellsfromapoptosisOneofthepossibleexplanationsforthisparadoxicalbehavioringliacellsmaybe
secondarytodifferentcapacitiesoftumorandnon-tumorcellstosynthesizeceramideinresponsetocannabinoids
Guzmanetal2006- 9patientswithGBMwhofailedsurgeryandXRT(60Gy)Medianage55AdministeredTHCaliquotsdailystarting3-6dayspost-opDecreasedcellproliferationoninvivosamples
Conclusion
Insufficientevidencetosupportorrefute
MMJTreatsCancer
• Olivia,7yo withdiffuseglioma ofthemidbrain• TP53mutation(Li-Fraumeni)• Receivingchemotherapy• GivenMMJdaily• Increasingdosestotreatandpreventcancer• HighCBDandlowTHC
MMJforNauseaControl:Maggie
• 5yo girldiagnosedwithaverageriskmedulloblastoma
• MMJonlyfornauseamanagement• Goodsymptomcontrol• Alsorefusedchemotherapy…
Chemotherapy-InducedNauseaandVomiting
Whitingetal2015- 5compounds
28trials(mostpriorto1984)- 8placebo,20comparators,2combotrialsAvgnumbersofptsshowedgreaterbenefitwithcannabinoidsthanwithplaceboNotallwerestatisticallysignificant
CochraneReview2015- nabiloneanddronabinol
23trials- placebo,cross-over,parallelMixedfindingsinplacebo(noneworsewithcannabinoids)NodifferencecomparedtoprochlorperazineModerateevidenceshowingpreferenceforcannabinoids
Only3trialswithchildren- nabiloneanddronabinol
Comparedtoprochlorperazine,metoclopramide,domperidoneOnetrial,THCat10mg/m2ondayofchemowassuperiortoprochlorperazineAnothertrialfoundnodifference
5/12/18
6
Conclusion
ConclusiveEvidencethatoralcannabinoidareeffectiveanti-emeticsforchemo-inducednauseaandvomiting
Lackofdataregardingplantcannabis,cannabidiol
Background—MMJforSupportiveCare
Darla,11yo girl,highriskPNET• (nowcalledSTNeuroblastoma)• Severemalnutrition/weightloss• “MMJreallyworks!”• “Tastesterrible”
Page: 21 of 56Page: 21 of 56 IM: 21 SE: 2IM: 21 SE: 2
Cancer-AssociatedCachexia
Strasseretal.2006- PhaseIIIRCT
Advancedcancerandweight-loss>5%over6monthrandomizedtoTHC+cannabidiol,THC,orplaceboBIDfor6weeksITTanalysisyieldednodifference
Jatoietal.2002- RCT
Advancedcancerand5lbweightlossover2monthrandomizedtodronabinolormegaceorcomboMegacewassuperior(75to49%,combo66%)
Cognition
2studies(Bluhmet.alandElMarrounet.al)examinedcognitivedevelopmentat36and60monthstothoseexposedtoTHC- nodifferencefound
Weakeffectonshorttermmemory
Goldschmidtetal.2012 - worsereadingscoresatage14onWechslerAchievementTest
Non-exposedchildren94score,thoseexposedtomorethanonejointperday87.8
Threeotherstudiesshowednodifferenceincognitiveormotordevelopment
OtherHealthEffects
MVI:20143.2%16-25yearoldsreporteddrivingwhileintoxicatedwithcannabis
SystematicreviewbyRogerbergin2016lookingatover230,000patientsshoweda20-30%higheroddsofMVCwithcannabisuse
Overdose: publicopinionitisa“safer”alternative
Severalcasereportsofingestionbyyoungchildrenleadingtorespiratoryfailureandcoma
Wangetalin201681casesinColorado- 44%obsinED,22admittedtoinptorICU,2requiredrespiratorysupport
OnecasereportofanadolescentdyinginpartsecondarytoediblesinColorado
MMJMedicalConcerns• Infectionrisk
• Baselineimmunosuppressionwithcancertreatment• ImmunecellshaveCB2receptors• Additiveeffectonimmunefunction?• Unclear“clean”procedures
• Prepareproductsfromplantsource• Potentialcontamination• Bacterialpathogens• Fungalpathogens
• Autoclave!
5/12/18
7
Aspergillus
Severalcasereportsregardingimmunocompromisedandcompetentpatientswithevidenceofaspergillosis
CannabiscanharborAspergillusspores
Case-controlstudyin1998byWallaceetal.inHIVpatientsshowednosignificantassociationbetweencannabisuseandaspergillosis
Only19patients
Consensusguidelinesuggestcannabisavoidanceinimmunocompromisedhosts
DrugInteractions
Inhibitorsof2C9,2C19and3A4mayincreasethepharmacologiceffectanddurationofTHC
—Macrolides(exceptazithromycin),oralcontraceptives,CBD,paroxetine,fluoxetine,sorafenib,cyclosporine,plussomeprotonpumpinhibitors,calciumchannelblockers&azoleantifungals
Inducersof2C9,2C19and3A4maydecreasethepharmacologiceffectanddurationofTHC
—Carbamazepine,rifampin,phenytoin,ritonavir,StJohnsWort,phenobarbital
CBDisastronginhibitorof3A4and2D6
—Mayincreaseeffectofcalciumchannelblockers,antihistamines,cyclosporine,busulfan,etoposide,tacrolimus,sirolimus &sildenafil
THCisaninducerof1A2
—Maydecreaseeffectoftheophylline,clozapine,chlorpromazine,cyclobenzaprine,dacarbazine
HOWDOHOSPITALSANDPROVIDERSRESPOND?
Recentstudyinpediatriconcology
• 288pediatriconcologyproviders• 32-itemsurvey• Multidiscproviders• 3centers(Boston,Chicago,
Seattle)• Providerswhoareeligibleto
certifywereactuallymorecautious
• Ananth P,MaC,Al-Sayegh H,etal.Providerperspectivesonuseofmedicalmarijuanainchildrenwithcancer.Pediatrics.2018;141(1):e20170559.Availableat:http://pediatrics.aappublications.org/content/141/1/e20170559.
HowourinstitutionhasaddressedMMJ
Thewidespreadavailabilityanduseofmarijuana-derivedproductsinColoradohascreatednewchallengesforourhospital.Asarefresher,ourCHCOMedicalMarijuana:PatientUsepolicyprovidesforacknowledgment(notendorsement!)ofmedicalmarijuanaproductsbyinpatients/families,whoarerequiredtosigntheCHCOMedicalMarijuanaReleaseandWaiverofLiabilityforminordertousetheproduct.Iamattachingahandoutwhichexplainsthestep-actionwherebyourinpatientteamscanacknowledgetheuseofmedicalmarijuanaproductssothatitwillappearunderthepatient’sMedicationList.SinceourhospitalpolicywasapprovedinMarchof2016,wehaverecognizedaneedtoprovideguidancetofamiliesandcareteamsinunderstandingstate/federallawandexpertiseinpotentialpharmacologicinteractionsofuseoftheseproducts. Tosupportourcareteamsinimplementationofourhospitalpolicyandourfamiliesinadvancingtheirunderstandingofmarijuana-derivedproducts,IampleasedtoannouncetheinitiationofourChildren’sHospitalColoradoinpatientCannabinoidEducationService,whichwillbeginnextMonday,July25th.ThisinpatientconsultativeservicewillbeateamapproachthatincludesaCHCOclinicalpharmacistandsocialworkerandwillbeavailableM-Fr8am-5pm.Uponrequestbythepatient’sprimaryservice,theteamwillmeetwiththeadmittedpatient/family,assessforanypotentialdrug:druginteractionsinvolvingthemedicalmarijuanaproduct,assessforanypatientsafetyconcerns,provideeducationtofamiliesaboutpertinentstatutesandtheCOmedicalmarijuanaregistry,andexplainthethatfamiliesmustsignifusingmedicalmarijuanaproductswithinourfacility.Theconsultteamwillthenmeetwiththeprimaryservicetodiscussfindingsandanyrecommendationsaswellasdocumenttheirfindingsinaconsultativenote.
CHCOCannabinoidEducationService
• ConsultantTeam:clinicalpharmacistandsocialworker• Role:
• Assessfordrug:druginteractionswithMMJproduct• Evaluateforanysafetyconcerns• ProvideeducationregardingpertinentstatutesandtheColoradoMedical
Registry• ComplywithhospitalrequirementofsigningMMJpolicywhileinpatient• Discussfindingswithprimarymedicalteam
5/12/18
8
LocalPolicyMedicalMarijuana-Providers
S/B:Thepolicy“Marijuana:PatientUseofMedicalMarijuana”wasreleasedMonday7,2016.Thispolicyoutlinestheprocessforacknowledgementofpatientuseofmedicalmarijuanaandallowsfordocumentationofmedicalmarijuanauseonthepatient’sMAR.Thisprocesswillbeusedbyproviders,pharmacistsandnurses.Toprovideeducationregardingthispolicy,thisdocumenthascompileddetailsofprocedurescontainedinthepolicy,theEPICworkflowforenteringinthemarijuanaacknowledgement,andreferenceinformationavailableonmarijuanause.WhatProvidersNeedtoKnow:
• TheuseofmedicalmarijuanawhilereceivinginpatientcareatCHCOisatthediscretionofthepatient’sprimaryservice.
• Thispolicyacknowledgespatientuse.However,CHCOanditsstaffdonotendorseorrecommenduseofmedicalmarijuanaproducts.
• IntheabsenceofamedicalmarijuanaregistrationcardthefamilywillbeprovidedinformationonhowtoparticipateintheCOmedicalmarijuanaregistry.
• Patients/caregiverswhohavecompletedtheCHCOReleaseandWaiverofLiabilityFormmaybeallowedtousemedicalmarijuanaproducts(oralortopicaldosageformsonly;nosmokingorthroughavaporizer).
o AspartoftheReleaseandWaiverofLiabilityprocess,alicensedphysicianand/orhealthcareproviderwhoisamemberoftheCHCOmedicalstaffmustadvisethepatient/familyofthepossiblerisksandbenefitsoftheuseofmedicalmarijuana.
• AfterCompletionofthewaiver,theproviderwillentertheacknowledgementintothepatientsEpic™profile(Describedintheworkflowbelow)forpharmacytoassessforknowndrug/drugordrug/diseaseinteractionspriortoapprovaloftheacknowledgement.
o NOTE:Forpatientsutilizingmultipledosageformsofmarijuanaproducts(e.g.oilsplusedibles)onlyONEacknowledgementneedstobeenteredintothepatient’sprofile.
• Withtheacknowledgementofmedicalmarijuanauseineffect,thefamilywillassumeallresponsibilityassociatedwithmedicalmarijuanastorageandadministration.
LocalWorkflowProviderWorkflow:
1. TheCHCOproviderscanaccesstheacknowledgementutilizingtheordersactivity
2. IntheorderssectionofEpic™,theproviderwillenteranacknowledgementofthepatient’sself-
administrationoftheproduct.a. NOTE:Thisacknowledgementcanbeaccessedbytyping‘medicalmarijuana,’
‘marijuana,’‘acknowledgement,’or‘cannabinoid’(oranypartofthosenames).
3. Oncetheacknowledgementisselected,theproviderwillberequiredtoanswerprompts
addressingthefollowingissues:a. Theacknowledgementwillincludetheprovider’saffirmationstatement:“Ihavebeen
informedaboutthispatient’s(orfamily’s)desiretoself-administermedicalmarijuanaproductswhileundermycare.Iacknowledgethispatient’s(orfamily’s)choice.”
i. NOTE:Bydocumentingthisnotetheproviderismerelycommunicatingacknowledgementtoanotherteammember,notnecessarilyindicatinghe/sheisrecommendingorendorsingtheuseoftheseproducts.
b. AdditionallytheproviderisrequiredtoacknowledgethattheCHCOreleaseandwaiverofliabilityagreementhasbeensigned
4. Uponcompletionoftheacknowledgementorder,thenurseandpharmacistwillbenotifiedper
usualEpic™workflow.
MMJConsultServiceCannabinoidEducationConsultService
• Toassistourinpatientteams,apharmacist/socialworkerteamcanmeetwithpatientsandfamiliesuponrequestbythepatient’sprimaryservice
• Thegoalsofthisservicearetoassessforpotentialinteractionsbetweenmedicalmarijuanaproductsandanyothermedicationsthepatientistaking,toassessforanysafetyriskstothepatient,andtoprovideeducationtofamiliesaboutpertinentstate/federallegislationandtheCOmedicalmarijuanaregistry,whereappropriate.
• Theconsultteamcanalsoprovideeducationtofamiliesaboutthehospital’smedicalmarijuanareleaseandwaiverofliability.
• Torequestaconsult,CANNABINOIDEDUCATIONTEAMcanbesearchedforasaninpatientorder–seescreenshotbelow:
BarriersToResearch
SeveralstepsinobtainingapprovalforScheduleIcontrolled-substanceincludingFDA,DEA,andstateapproval
LastattemptatchangingtoScheduleIIfailedin2016
Untilrecently,onlyonesiteprovidedMMJforapprovedresearch(UniversityofMississippi)
NoFDAapprovalformajorityofcompoundsconsumedrecreationally
MedicalMarijuanaAct- inhousesub-committeecurrently
MMJStudyinColorado
• ProspectiveobservationalstudyofMMJonthequalityoflife(QOL)inpediatricbraintumorpatients
• Laboratoryassessmentsofwhitebloodcellfunction• FundedbytheColoradoDepartmentofHealth• Nursesarethefrontlinefordiscussionswithpatientsabout
MMJandmustbeawareoftheemergingfieldofMMJinpediatriccancer.
ExternalWebsiteStudyInformation
5/12/18
9
StudyDesignOverview
• Prospectiveobservationalcohortstudyevaluatingthequalityoflife(QOL)ofchildrenwithCNStumorsandtheirfamilieswhochoosetoself-medicatewithMMJproducts
• Gatherinformationregardingpotentialclinicalefficacy,impactonimmunefunction,cannabinoidpharmacokineticsinchildren,andpotentialtoxicities/complications
StudyDesignOverview
• PediatricQualityofLifeInventory(PedsQL™)cancer,braintumorandfamilyimpactmodulesattimeofenrollment(priortocannabinoidtherapy)andatserialtimepointsduringcannabinoiduse
• Patientswillserveasowncontroltolimitpotentialconfoundingfactorsrelatedtotypeoftumor,treatmentregimen
• Serialblooddrawswillbeperformedtoassessimmunefunctionandcannabinoidlevels
MMJStudyOutcomeMeasures
• PrimaryoutcomeismeasurementofoverallQOLscoresinchildrenwithCNStumorsasassessedbythevalidatedPedsQL™braintumor(PedsQL™-BT)module
• SecondaryoutcomesincludechangesinspecificsubscoresofPedsQL™cancerandbraintumormodulesandtotalscoresforPedsQL™familyimpactmodule
MMJStudyInclusion/ExclusionCriteria
• InclusionCriteria• Age>2yearsand< 18yearsatthetimeofstudyenrollment• Patientsmusthaveadiagnosisofcentralnervoussystem(brainorspinal)
tumor• PatientsmustbeONEofthefollowing:
• Undergoingdisease-directedtherapy,palliativetherapy,ortransferringtocareunderthePediatricNeuro-OncologyphysiciansatCHCO
• Interestinmarijuanausehasbeendiscussedbythepatientorparents.
• ExclusionCriteria• Patientbegantherapywithcannabinoidsmorethan72hourspriortothetime
ofconsent.
MMJStudyDesign
• CHCO-developeddiarywillbeadministeredtogatherdataregardingmarijuana/cannabinoidusepractices• Producttype/strain• Methodofdelivery(i.e.,edible/oil/inhaled)• Perceivedsideeffects• Financialimpactonthefamily(togatherdataregardingout-of-pocketcostsforthisalternative
therapy)• Diarieswillalsorecordnausea,painandappetitemedicationsrequired
• Clinicaldatawillalsobecollected,includingage,gender,tumortype,diseasestatus,chemotherapytreatment,radiationtherapy,andcomplications(includinginfections)
• Datacollectionisatstudyentry,3,6,and9monthtimepoints
MMJBiologicCorrelativeStudies
• Immunefunctionatserialtimepoints• T-cell(ForemanLaboratory)• Neutrophil(AmbrusoLaboratory)
• Cannabinoidbloodlevelsatserialtimepoints• AssociationwithhigherCBD/THC/metaboliteswithchangesin
PedsQL™assessments?• Contributetoscienceinabiggerway!
5/12/18
10
MMJSubstudyinPalliativeCare
• Tobedoneincollaborationwithhospices• UsedmethodsdevelopedbyCHCONeuro-Oncologyteam
usingunexpectedadmissionandstructuredinterviewswithparentsafterdeathtoassessqualityofterminalcare(HaveconsiderableamountofpriordataforpatientsnotonMMJ)
• AssessimpactofMJusageontheneedforIVmedicationssuchasversedandopioids.
NursesRoleinMMJ:Legality
• Wheredoesthepatientreside?• Whatageisthepatient?• Consequencesforusingillegally• Howtoobtaina“RedCard”• MedicalMarijuanaClinics• Dispensaries(Recreationalvs.Medical)
NursesRoleinMMJ:Education
• Learnaboutyourstate’sregulations• DepartmentofHealthWebsite• CannabisEducation
• Web-basedseminars• Universityoffered
• Visitaclinicanddispensary• Learnthelingo
NursesRoleinMMJ:PatientEducation
• Talkaboutit!• Askiftheyareusingany
MMJproducts• Dosing---lowandslow• Strains• Products• Safety• SideEffects• Interactionswithother
allopathictherapies
Challenges
• Financial• Clinicfee• Medicalmarijuanacard• Product
• SocialSupport• ClinicalStaff• FriendsandFamily
• Barriers• Travel• Camps• SchoolAdministration
What’snext??
• AbilitytoresearchMMJwiththesamestrengthofresearchwecandowithothermedications
• NationalregulationsforMMJ• Standardizationofproducts• Cleanerprocessingoftheproduct• Education• Collaborationbetweendisciplines
5/12/18
11